Try our Advanced Search for more refined results
Life Sciences - September, 2021
317 articles
- 'What's The Evidence?' Calif. Judge Asks After Big Opioid Trial
- 11th Circ. Hands Catalyst Win In 'Orphan Drug' Case
- Allergan Must Face Generic Drug Price-Fixing Claims
- Sun Pharma's Eye Pain Patent Invalidated
- Fed. Circ. Forecast: Verisk Targets EagleView's $375M Win
- Cherokee Want Pharmacies In State Court After Opioid Deal
- Gunderson-Led Theseus Pharma To Launch $125M IPO
- Texas Court Puts Gilead Medicaid Fraud Suit On Ice
- MacroGenics Escapes Investor Stock Drop Suit
- Vaxart Buried Investors In 'Avalanche Of B.S.,' Judge Says
- J&J Sunscreen Carcinogen Suits Doubtful For MDL In NJ
- Westco Chemicals 401(k) Settlement Rejected Over Fairness
- Mass., West Pa. Cited As Viable Homes For Philips CPAP MDL
- Deals Rumor Mill: Willis Towers Watson, Huntsman, Fanatics
- Covington, Ropes Lead Merck's $11.5B Acceleron Pharma Buy
- Device Co. Can Search Tim Cook's Emails In Apple Patent Suit
- Celgene Ended Theranos Deal Early Over Bad Data, Jury Told
- 7 Key Details As Pharmacy Giants Head To 1st Opioid Trial
- Bills To Cut Drug Prices, Fight Counterfeits Sent To Full House
- Split 9th Circ. Revives Calif. Chemical Water Case
- Judge Orders Mallinckrodt Trial On Acthar Antitrust Claims
- New Calif. Law Expands Access To Medical Pot In Hospitals
- Boeing Case Highlights Risk For Health, Life Sciences Boards
- Vein Filter Victim Calls On Pa. Justices For Tort Law Shake-Up
- Del. Judge Invalidates Stanford Kidney Test Patents
- Court Rejects Challenge To Ill. Cannabis Licensing Scheme
- What 9th Circ. Privilege Test Means For Dual-Purpose Advice
- Sidley Austin Snags 3 Former FDA Attys From Hogan Lovells
- Ex-Insys Sales Rep Admits Guilt On Day 4 Of Kickbacks Trial
- Truck Co. Navistar Must Face Suit Over EPA Standards Claims
- AstraZeneca Buys Rare Disease Drugmaker For Up To $500M
- Holmes Texts Show Investor Cash Poured In As Lab Struggled
- Public Health Groups Urge FDA To Speed Up E-Cig Reviews
- Herbalife Trims But Can't Escape $1B Fraud Suit
- DC Circ. Hears DEA Should Not Oversee Hemp Manufacturing
- FTC Settles Antitrust Case Against Alabama Dental Board
- In COVID Fight, Nonprofits Ask White House For IP Waivers
- 'Overheated': How A Chinese-Spy Hunt At DOJ Went Too Far
- SEC Says Cannabis Pill Maker Ran $2M Securities Fraud
- J&J Wins Multiplaintiff Mo. Talc Trial After High Court Setback
- Drug Cos. Say DA's Opioid Settlement Objections Are Unripe
- Male Ex-Worker Drops Pay Bias Suit Against Emory U.
- Lifting The Veil On The Supreme Court's Shadow Docket
- Endo Agrees To $7.5M Deal With La. AG Over Opioid Claims
- College Of NJ Students Aim To Block COVID Vaccine Mandate
- Cherokee Nation Inks $75M Opioid Deal With Distributors
- NY Bankruptcy Judge Who Oversaw Purdue Ch. 11 Will Retire
- 3 Patent Eligibility Reform Ideas Add Clarity But Bring Risks
- Leahy's Bill Seeks To 'Course Correct' From Iancu's PTAB
- Prop 65 Judge Out, Slams Bid's 'Aggressive' Privacy Invasion
- 1st Circ. Backs Convictions Of NECC Execs In Meningitis Case
- Tilray Gets Securities Fraud Claims Tossed For Now
- Zetia Buyers Renew Class Cert. Push After 4th Circ. Snag
- Romney, Kaine Press FDA On Delayed E-Cigarette Decisions
- McKesson Tells 9th Circ. Opioid FCA Suit Correctly Dropped
- Shkreli's Pharma Venture Loses Bid To Limit Profit Payback
- FTC Deepens Look At $1B Medtronic-Intersect Deal
- 8 Firms Guide 3 Cos. For $969M In Planned IPOs
- King & Spalding, O'Melveny Rep DL Unit's $2.5B Kraton Buy
- Insys Manager Asks Full 1st Circ. To Review 'Pill Mill' Guilt
- NJ Judge Refuses To Knock Down Rutgers Vax Requirement
- FlatWing Won't Get $690K Atty Fees In Pfizer Unit Patent Fight
- BASF, Cahill Gordon To Pay $22.5M Atty Fees In Asbestos Suit
- J&J Says Cyprus Can't Intervene In Imerys Coverage Fight
- NY Judge Won't Rush Ruling On City's Vaccine Mandate
- Embracing ESG: United Natural Foods GC Talks Bottom Line
- Theranos Execs Put PR Over Patients, Ex-Lab Chief Testifies
- Servicemembers Want Injunction Against DOD Vax Mandate
- Virginia Doctor Pleads Guilty In $1.8M Rx Fraud Scheme
- House Narrowly Approves Abortion Rights Bill
- Novo Nordisk To Pay $100M To Settle Investor Class Action
- COVID Test Maker, Analytics Firm Price IPOs Totaling $740M
- Arb. Clause Applies To MDs In Vaccine Suit, 3rd Circ. Told
- California AG Announces Appeal Of Purdue Ch. 11 Plan
- Miss. Lawmakers Reach Deal To Legalize, Tax Medical Pot
- What Plaintiffs Can Do If J&J Succeeds In Bankruptcy Strategy
- 3 Attorney Ethics Considerations For Litigation Funding
- Calif. Jury Awards $5M In Landmark Cannabis Antitrust Case
- Real Estate Rumors: Kolter Homes, Savanna, DR Horton
- Perkins Coie Snags Obama Vet For Offshore Wind Push
- 11th Circ. May Wait On High Court Ruling In Ga. Abortion Case
- Linda Evangelista Files $50M Suit Over 'Disfiguring' Procedure
- Monsanto PCBs Contaminated Del. Waterways, AG Suit Says
- Mich. Doctor Convicted In $100M Injections-For-Pills Scheme
- PTAB Upholds Bulk Of Claims In Medtronic Patents
- CytoDyn Investors Challenge Director Removal Rule In Del.
- MVP: Cohen Milstein's Sharon K. Robertson
- GE Healthcare Inks $1.45B Deal For Surgical Imaging Co.
- Insurer Wants 3M To Pay Up For Warming Device Defense
- Gov't Employees Sue Over Biden's COVID-19 Vax Mandates
- Chubb Slams Sweep Of Opioid Defense Order For Rite Aid
- Pot Researcher Urges 9th Circ. Redo Of Classification Appeal
- FDA Greenlights Pfizer Vaccine Boosters For COVID
- Aldi Freed From False-Ad Claims Over 'Vanilla' Almond Milk
- US Trustee Challenges Constitutionality Of Purdue Releases
- Watchdog Says DOD Drug Supply Chain At Risk For Upheaval
- Chancery Says Takeda Liable For AbbVie's Lupron Supply Lag
- How ABA Opinion Shifts Alternative Biz Structure Landscape
- Telehealth Providers Must Beware Of Fraud As Industry Grows
- Senate Panel Grills Biden's Pick For HHS Watchdog
- Pharma Giants' $454M Glumetza Antitrust Deal Gets Initial OK
- FCA Proposal Is Unfair And Would Hinder Economic Growth
- Mattis Doubted Theranos 'Transparency,' Holmes Jury Hears
- Plaintiff Fact Sheets In Mass Tort Discovery: Keys To Success
- MVP: Keker Van Nest's Laurie Mims
- Latham Hires Vinson Veteran For Energy M&A Practice
- United Airlines Faces Bias Suit Over COVID-19 Vax Mandate
- Pharmacies Win Remand Of FDA's Compounded Drug Memo
- Theranos Test Wrongly Suggested Miscarriage, Jury Hears
- Elysium Gets Dartmouth Vitamin B3 Patents Axed Under Alice
- 100s Of Attys Air Warring Views In High Court Abortion Fight
- Ohio Counties Want Unvaxxed Jurors Out Of Opioid MDL Trial
- PwC Can't Shed City's Claim In Valeant Securities Suit
- AbbVie Calls Retailers' Bystolic Generic Delay Claims Flawed
- Vaping Industry Rips Into FDA After Nearly 1M Products Pulled
- Attys Seek $610K In $1.8M Dollar General False Ad Settlement
- Blackstone Unit To Invest £850M In UK Lab Space
- Paragard IUD Maker Wants 'Shotgun' MDL Claims Tossed
- MVP: Skadden's Jennifer Bragg
- Sandoz Infringed Amgen's Psoriasis Drug Patents, Court Says
- J&J May Court Trouble With 'Texas Two-Step' Talc Gambit
- Barbados Co. Says $12M COVID Vaccine Deal Was A Scam
- Lupin Will Pay $150M To End Glumetza Antitrust Suit
- Imerys Ch. 11 Vote Change Challenged By Del. Judge
- Justices Set Abortion Fight Oral Arguments For Dec. 1
- Bausch Execs Escape Derivative Suit Over Fraud Scheme
- Pressure Mounts On USPTO To Join Drug Pricing Fight
- Hemp Equipment Co. Denies $45M Fraud Suit Implicates It
- Embracing ESG: HPE Counsel Talk Effective Board Oversight
- Illumina's Early Deal Close Draws EU 'Interim Measures'
- Judge Limits Stanford Doctor's Testimony In Opioid MDL
- No 'Bad Faith' To Justify Fee Award In Docs Suit, Biogen Says
- MVP: Gibson Dunn's Jane M. Love, Ph.D.
- Justices Told 2nd Circ. Ruling Puts Well-Known TMs At Risk
- Bankruptcy Courts' Equitable Discretion May Be In Danger
- Ropes & Gray-Led Lab Space Provider Lands $250M Series B
- Holmes Rushed Device Testing For Walgreens Deal, Jury Told
- Travelers Doesn't Owe Northrop Coverage In Pollution Suits
- Rosen Law Firm To Lead Investor Suit Against Botox Rival
- Endo's Attys In 'Career-Wrecking' Peril As Opioid Woes Grow
- Ex-Mylan Info Tech VP Cops to $8M Insider Trading Scheme
- Family of Pilot Killed Fighting Wildfire Sues Helicopter Maker
- Myriad Board Under Fire For Allegedly Overselling Gene Test
- Insurer Asks 9th Circ. To Affirm Opioid Coverage Dispute Win
- Fed. Circ. Upholds ITC Infringement Finding On Milk Patent
- 3rd Circ. Preview: Antitrust, Defamation Suits Kick Off Fall
- DePuy Escapes Implant Suit After Expert Is Limited
- AI Inventorship Decision Leaves Open Questions
- Pot Grower Says Careless Cigarette Toss Caused $40M Fire
- Polish Pharma Co. Gets Arbitration Bid OK'd In IP Fight
- Justice Gap Demands Look At New Legal Service Models
- 3 Firms Win $1.3M In Fees From Zynerba CBD Gel Settlement
- Health Hires: Holland & Knight, Arnall Golden Gregory
- FDA Panel Backs Pfizer COVID Booster For Some Groups
- Judge OKs $2M Preliminary Deal in Indivior Stock Drop Suit
- MVP: Ropes & Gray's Hannah H. England (Freeman)
- DOJ Targets Telemedicine Fraud In $1.4B Enforcement Action
- JSR Pays $514M For Inpria To Strengthen Semiconductor Biz
- UK Litigation Roundup: Here's What You Missed In London
- Cybercrime Spree Raises Risks Of Insurance Coverage Battles
- Grifols Grabs German Plasma Co. At €2B Enterprise Value
- Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself
- Ohio Cuts $808M Opioid Distributor Deal Plus $42M Legal Fee
- Vitamin C Cos. Want Third Shot At 2nd Circ. In Price-Fix Case
- IP Forecast: Trial Lawyer School TM Fight Lands At 10th Circ.
- Trulieve Seeks Exit From Noncompete Row Over Exec Hiring
- Galena Settles Investors' Revived Opioid Row For $1.6M
- Imerys Tort Claimants Want To Change Ch. 11 Vote To 'Yes'
- Patient Says Removal Of Ethicon Mesh Didn't Tip Her To Injury
- Deals Rumor Mill: Stripe, Novolex, Unilever
- Skadden, Kirkland Lead Prenetics' $1.7B SPAC Deal
- Philip Morris' £1.1B Vectura Buy On Track Despite Objections
- Apple Wants Fed. Circ. To Rethink Refusal To Toss Patent Suit
- Becton Beats FDA Approval Claims In Securities Suit
- Pa. AG Says DAs Can't Sue To Stop $26B Opioid Settlement
- Judge Erred By Nixing $3M From Verdict, 1st Circ. Finds
- US Trustee To Appeal Sackler Releases In Purdue Ch. 11
- David Boies Threatened Theranos Whistleblower, Jury Told
- 9 Companies Storm Capital Markets With IPOs Totaling $3B
- Impax Wants High Court To Undo 5th Circ. Loss To FTC
- Allergan Cuts Deal With Generic Cos. Over Depression Drug
- 4 Firms Seek To Lead Biotech Stock Promotion Scheme Suit
- How SPAC Investors Might Rethink Material Adverse Effect
- Ivantis To Pay $60M To End Patent Fight Over Glaucoma Tech
- FDA Biosimilar Approval Foreshadows IP Litigation Issues
- Willkie Farr Exec Says Attys Have Shown They Can Be Remote
- Court Won't Rush Feds' Decision On Protecting Ancient Fish
- Pa. Justices Won't Review Housing Rules For Medical Pot
- Omnicare To Pay $1M To Settle Drivers' Misclassification Suit
- Goodwin Nabs Dechert IP Partner For Life Sciences Team
- Holmes Fan's #MeToo Callout To Jurors Draws Judge's Ire
- Biden Admin. Hit With 1st State AG Suit Over Vax Mandate
- CDC, FDA Issue Warnings About Delta-8 THC 'Weed Light'
- Apotex, Mylan Urge Full Fed. Circ. To Ax Cancer Drug Patent
- Fla. Biotech Co.'s Misleading IPO Hurt Investors, Suit Says
- USCIS To Require Full COVID-19 Vaccination To Immigrate
- 'Red Flag' Expert's Opinion Limited In Opioid MDL
- Mallinckrodt Aims To Push Back Ch. 11 Plan Hearing Until Oct.
- Generics Group, Intel Back Mylan's Fintiv Fight At High Court
- Zydus, Takeda Tell 3rd Circ. Antitrust Appeal In Right Place
- Fed. Circ. Told Inventor Limits Don't Bar Validity Challenge
- Rutgers Students Can't Remove Judge In COVID Vaccine Suit
- After Gerber HQ Mix-Up, Judge Moves Baby Food Case To Va.
- These Firms Have The Most Women In Equity Partnerships
- Greenberg Traurig Taps Ex-FDA Atty For Litigation Team
- 2nd Circ. Vitamin C Price-Fixing Decree Goes Beyond Antitrust
- High Court's Legitimacy Tested In Abortion Row, Justices Told
- FDA Wants To Team Up With USPTO Over Drug Pricing
- FDA Asks Full DC Circ. To Consider Electric Shock Device Ban
- Pot Growers Say Calif. Cops Ran Extortion Ring In RICO Suit
- AbbVie Escapes Shareholder Suit Over Failed Shire Merger
- Cyprus Mines Asks To Join Imerys Ch. 11 J&J Suit
- Mallinckrodt Creditors Say Ch. 11 Plan Understates Revenues
- Balwani's Counsel Can't Reserve Seats To Watch Holmes Trial
- Embracing ESG: Leidos GC Talks Social Responsibility
- Purdue Pharma Gets OK For $7.1M In Exec Incentives
- J&J Says Plaintiff Firms Can't Hide From Talc Media Subpoena
- Dual MD, JD Partner Joins Foley Hoag In DC
- Retina Drug Co. Settles Investor Row For $29M
- Law360's Glass Ceiling Report: What You Need To Know
- Pharma Cos. Should Prepare For New Drug-Rebate Scrutiny
- J&J Targeted Overweight Women For Talc Sales, Jury Hears
- Oklahoma Pot Grower Says It Was Caught In Law Firm's Scam
- UK Watchdog Fears 'Race To Bottom' On COVID Testing
- Teva Loses Bid To Dodge Most Of Feds' FCA Case
- What's At Stake In High Court's CVS Disability Bias Case
- Haynes And Boone Launches CBD, Hemp Industry Practice
- 15 Firms To Guide IPOs Exceeding $3.4B As Activity Resumes
- CBP Removes Top Glove From Forced Labor Blacklist
- J&J Courted 'Death And Destruction' With Talc, Jury Hears
- Endo Strikes $50M Opioid Deal In NY Amid Trial Tumult
- HHS Targets Drug Prices In New Proposal
- Elizabeth Holmes' Fraud Trial Delayed Over Virus Concerns
- Allergan Investor Class Certified With New Lead Plaintiff
- Jury Hands CR Bard A Win In Ohio Hernia Mesh Bellwether
- 11th Circ. Nixes Emory Doctor's Race Bias Suit
- Pharma Giants Ink $300M Deal To End Glumetza Antitrust Suit
- Pacific Legal Backs Challenge To Drug Program Cuts
- Shkreli Antitrust Trial Slated For Mid-December
- Sierra Club, Others Say EPA Must Close Emissions Loopholes
- FDA Delays On Juul, Orders Other E-Cigs Off Market
- Unvaccinated Aegerion Rep Can't Delay Prison, Feds Say
- 9th Circ. Backs Class Cert. In Theranos Blood Test Suit
- Lessons In Crisis Lawyering 20 Years After 9/11
- Mylan Pushes Back Against EpiPen Buyers' Appeal Bid
- Opioid MDL's Tribal Bellwether Paused, Global Deal Possible
- Nonprofit Sues FDA Over Unanswered Hair Loss Drug Petition
- Ga. Sterilizer Says Alleged Cancer-Causing Emissions Legal
- Insurers Beat Benecard's 3rd Circ. Fraud Suit Coverage Fight
- Biz Groups Ask Harris To Push Mexico To Enforce Trade Deal
- Student Vaccine Mandate Considerations For Private Schools
- Mallinckrodt Pushes Back Ch. 11 Plan Vote After $583M Deal
- Bid Protest Spotlight: Informalities, Reevaluation, Ethics
- Neb. Medical Pot Legalization Activists Eye 2022 Do-Over
- Ill. Judge Gives Final OK To $800K Deal Over Drug Faxes
- CPAP Maker Sued Over Recall For Chemical Inhalation Risk
- PTAB Wipes Out BASF Patent On Fatty Acid
- Patent Owner Estoppel Isn't As Threatening As It Seems
- AbbVie Loses Chancery Fight For Takeda Contract Injunction
- Insurer Should Defend Opioid Suits, Ohio Court Told
- Holmes' Fraud Trial Openings Draw Crowds, Look-Alikes
- Trulieve Settles Hiring Class Action After Cert.
- 4 Firms Craft Perrigo's $2.1B Deal For PE-Owned Self-Care Co.
- From Boies To Mattis, Theranos Trial Promises VIP Witnesses
- CVS Tells High Court Mailed Prescriptions Not Disability Bias
- Ex-Pharma HR Head Aims To Revive Japanese Favoritism Suit
- Chicago's Discovery Bid A Defective 'Attack,' Endo Says
- US Report Shows Pandemic's Toll On International Trade
- The Regulatory Growing Pains For Digital Health Companies
- SpineFrontier Execs Hit With Charges In Kickback Scheme
- Mich. Sens. Aim To Ax Morality Clause From Medical Pot Law
- AbbVie Settles Patent Dispute Over Muscle Stimulation Tech
- Lead Counsel Battle Heats Up In $1.8B Biotech Sale Suit
- Court Says Counterclaims In Pot Software Row Can Proceed
- Rutgers Students Seek To Oust Judge In COVID Vaccine Suit
- SEC Says Mallinckrodt Ch. 11 Plan Releases Should Be Opt-In
- Ark. Suit Against Pot Law Firm May Require Arbitration In NY
- Fed. Circ. Affirms Bristol-Myers, Pfizer Win In Eliquis IP Row
- Purdue's 'Bitter' Pill For Victim Recoveries Here To Stay
- Bard Denied Early Win In Hernia Mesh Bellwether
- No Excuse To Delay Discovery, Mallinckrodt Claimants Say
- Snell & Wilmer Adds IP Pro To Growing San Diego Office
- Teva Drops Claim That Rival Slowed Generic Development
- Epstein Becker Opens Ohio Office With 12-Partner Group
- IP Forecast: Herman Miller Readies For Chair TM Fight
- Chickasaw Want Arbitration Order Tossed In Rx Payback Suit
- DEA Letter On Psychedelics Is Agency Action, 9th Circ. Hears
- The Latest Fed. Circ. Antibody Rulings You Need To Know
- Alexion Must Face Claims Of Stalling On Drug After Merger
- Pharma Co. Beats Shareholder Suit Over Migraine Drug
- Celgene Can't 'Guess' How Rival Mylan Operates, Judge Says
- Calif. Jury Empaneled In Trial Of Ex-Theranos CEO Holmes
- Northern Calif. County Dismissed From Pot Farm Raid Suit
- DC Circ. FCA Ruling Raises Bar For Alternate Remedies
- Lab Maker Says Ex-Exec Stole 10,000 Docs For New Employer
- Swedish Drug Co. Backs $8B Buyout Offer From Advent, GIC
- Why Structured Data Is Increasingly Important To Your Case
- Sullivan & Cromwell, Wachtell Rep $12.4B Deal For Hill-Rom
- Holmes Trial Jury Pool Narrowed For Final Day Of Selection
- 3 Firms Vie To Lead Stock Drop Suit Over Vax Candidate
- Another Federal Judge Tosses An Investor Suit Over Diversity
- Pot Giants Ayr, Planet 13 Ink Deals Worth $135M Combined
- Ex-Drug Distributor CEO Slated For January Opioid Trial
- Endo Beats Investors' Opioid Crisis Class Suit, For Now
- Law Firms Aim To Sink J&J Subpoenas For Talc Media Info
- Chancery Throws Out Challenge To $5.1B Tesaro Sale
- Eli Lilly Favors Millennial Applicants, Older Job Seekers Say
- Walmart Is Latest Co. Hit With Baby Food Heavy Metal Suit
- Surgical Implant Co. Settles Securities Suit For $10.5M
- Indivior's Suboxone Patent Fight Faces Wary Fed. Circ.
- Embracing ESG: AIG Counsel Talks SEC Risk Alert
- Procter & Gamble Slips 'Natural' Pantene Shampoo Label Suit
- Purdue Pharma Ch. 11 Plan Gets OK With Sackler Releases
- Fed. Circ. Teva Ruling May Shake Up Skinny Label Strategies
- Latham Opens Austin Office With Focus On Emerging Cos.
- Belcher's Withheld Prior Art Again Dooms Drug Patent Suit
- PE Firm AGIC Capital Clinches $1.2B For 2nd Fund